RecruitingNot ApplicableNCT06360653
a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer (SISTER-RAY)
Sponsor
ARNAS Civico Di Cristina Benfratelli Hospital
Enrollment
60 participants
Start Date
May 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Age 18-80 years
- ECOG PS ≤ 2 or KPS ≥ 70%
- Patients diagnosed with endometrial cancer (endometrioid, serous cell, clear cell, carcinosarcoma) FIGO stage IB-IIIC1 candidate to post-operative external beam radiotherapy, based on molecular and histological findings
Exclusion Criteria5
- Written Informed Consent
- Prior pelvic radiotherapy
- Para-aortic lymph nodes involvement
- ECOG PS ≥ 3
- Any diagnosis of inflammatory bowel disease (both active or quiescent)
Interventions
RADIATIONStereotactic Post-operative Radiotherapy for Endometrial Cancer
Patients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06360653
Related Trials
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT072094497 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706879 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT0627649116 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504232 locations